Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
Status:
Unknown status
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The NSCLC patients who experienced good clinical responses to an EGFR-TKI will inevitably
develop acquired resistance. A great deal of research are focusing on this issue. Arsenic
trioxide showed efficacy and safety in acute promyelocytic leukemia, multiple myeloma and
other solid tumors. Moreover, preclinical studies showed arsenic trioxide can reduce the
resistance of tumor cells to chemotherapy and TKIs.